HOME >> MEDICINE >> NEWS
Maxim Phase II Clinical Trial Highlights Substantial Increase In Leukemia-FreeSurvival For Acute Myelogenous Leukemia Patients

Clinical Results Will Be Presented Today at 1998 American Society of Hematology (ASH) Conference

San Diego, CA, December 7, 1998 - Maxim Pharmaceuticals (AMEX: MMP, SSE: MAXM) announced updated results from an ongoing Phase II clinical trial of its lead drug Maxamine® in patients with acute myelogenous leukemia (AML). The results from the trial suggest encouraging increases in leukemia-free survival in AML patients treated in remission with Maxamine Therapy.

The updated results will be presented today by Mats Brune, M.D., and Elisabeth Wallhult, R.N., Department of Hematology, Sahlgrenska University Hospital, Gothenburg, Sweden, at the American Society of Hematology Conference in Miami, Florida. "We are very pleased with the number of patients that remain in leukemia-free remission," said Dr. Brune.

The strength of the Phase II data led Maxim to commence a Phase III clinical trial of Maxamine as a remission therapy for AML patients. The Phase III trial, which began earlier this year, is underway in 11 countries and more than 100 clinical sites around the world. "The number of clinical sites that have approached Maxim and agreed to participate in this trial has greatly exceeded our expectations," said Dr. Kurt Gehlsen, chief technical officer of Maxim. "We believe that this interest results from the promising data we have seen in the Phase II trial for this population of patients who have limited options for therapy today."

Background on AML

AML is the most common form of acute leukemia in adults, and prospects for long-term survival are poor for the majority of patients. There are approximately 20,000 new cases and 15,000 deaths caused by AML each year in the United States, Europe and Australia.

Once diagnosed with AML, patients are typically treated with chemotherapy, and the majority achieve complete remission ("CR"). Unfortunately 75-80% of patients who achieve their first CR ("CR1") will relapse, and the medi
'"/>

Contact: Amy Flood
a.flood@noonanrusso.com
415-677-4455 x211
Noonan/Russo Communications
7-Dec-1998


Page: 1 2 3 4 5 6

Related medicine news :

1. Elan and Biogen Idec announce results from Phase III maintenance trial of Antegren
2. Phase II trial of anthrax vaccine to begin
3. NIAID Phase III HIV vaccine trial to determine correlates of protection will not proceed
4. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
5. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
6. Penn researchers announce results of Phase I trial using combretastatin drug
7. Anti-cocaine vaccine produces antibodies and is shown to be safe in Phase 1 study conducted by Yale researcher
8. Results of NUVANCE (IL-4 receptor) in Phase I/II study in asthma patients featured at AAAAI Late-Breaker Abstract and Asthma Therapy Sessions
9. ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia
10. Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease
11. Immunex Advances CD40 Ligand To Phase II Clinical Trial In People With Metastatic Kidney Cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/28/2020)... ... June 26, 2020 , ... PathAI, a global provider of artificial ... exploratory analysis of digital scoring of PD-L1 expression to assess response in patients treated ... the 2020 American Association for Cancer Research (AACR) Annual Meeting. AACR was held June ...
(Date:6/28/2020)... ... 26, 2020 , ... The Coronavirus pandemic created shortages in ... supplier of top-quality masks, sanitizers and thermometers, Trusted PPE is a woman and ... observed, “All of our masks are manufactured to medical standards in FDA-certified factories, ...
(Date:6/28/2020)... ... 27, 2020 , ... The FSHD Society announced the opening ... the organization’s history. The online conference takes the place of FSHD Connect, the ... year due to COVID-19. Nearly 300 individuals and families living with FSHD are ...
(Date:6/25/2020)... ... June 25, 2020 , ... Pivot Point Consulting, a national ... Firm, expanded its telehealth services to provide end-to-end solutions from strategy ... a Consulting Magazine “2020 Women Leaders in Technology” award winner, Laura Kreofsky ...
(Date:6/24/2020)... ... June 24, 2020 , ... Evolved Naturals, a new ... new website at http://www.evolvednaturals.com The newly launched website showcases a variety of ... oils , and a comprehensive line of skincare & topical products . , ...
Breaking Medicine News(10 mins):
(Date:7/7/2020)... Nova Scotia (PRWEB) , ... July 07, 2020 ... ... rebrand. Established in 2017, the company began as a hair service provider. Now ... both in-office and work-from-home employees. Bright’s expanded offering includes beauty amenities as well ...
(Date:7/2/2020)... (PRWEB) , ... July 02, 2020 , ... ... Look at Medical Conditions that Chiropractors Treat. , “From migraines to anxiety ... certain medical conditions,” according to the company. , Sourced from physician recommendations ...
(Date:7/1/2020)... ... July 01, 2020 , ... Lumeda Inc. (“Lumeda”), ... the formation of its Scientific Advisory Board with the appointment of a panel ... advice to support company development and introduction of its PDT products to the ...
Breaking Medicine Technology:
Cached News: